OncLive SOSS

Authors

David L. Saltman, MD, PhD

Latest:

Dr. Saltman on the Use of the DetermaIO Assay to Inform Immunotherapy Use in Advanced-Stage NSCLC

David L. Saltman, MD, PhD, discusses the use of the 27-gene Determa immuno-oncology assay to inform use of single-agent immunotherapy in patients with advanced-stage non–small cell lung cancer.

Jacob G. Scott, MD, DPhil

Latest:

Dr. Scott on the Incorporation of GARD-Based Radiotherapy Dosing in Oncology

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Catherine Lai, MD, MPH,

Latest:

Dr Lai on NCCN Guideline Updates in AML Maintenance Therapy

Catherine E. Lai, MD, MPH, discusses NCCN guideline updates regarding AML maintenance therapy, sharing how these updates influence treatment decisions.

Andrea Sitlinger, MD, Duke University Cancer Institute

Latest:

Updates in the Management of Hairy Cell Leukemia

Spyridoula Vasileiou, PhD

Latest:

Dr. Vasileiou on the Potential Role of ALVR109 for the Treatment of COVID-19

Spyridoula Vasileiou, PhD, discusses the potential role of ALVR109, a SARS-CoV-2 virus–specific T-cell therapy, for the treatment of coronavirus disease 2019.

Paulina J Haight, MD

Latest:

Dr Haight on Predictors of Treatment Toxicity in Gynecologic Malignancies

Paulina J Haight, MD, discusses predictors of toxicity and treatment response with lenvatinib and pembrolizumab in patients with gynecologic malignancies.

Natalie I. U. Vokes, MD

Latest:

Dr Vokes on Targeting HER3 in NSCLC

Natalie Vokes, MD, discusses emerging biomarkers in non–small cell lung cancer, specifically highlighting the promise of HER3-targeted therapy.

Steven J. Chmura, MD, PhD

Latest:

Dr. Chmura on the Management of Oligometastatic Breast Cancer

Steven J. Chmura, MD, PhD, discusses the current management strategies for oligometastatic breast cancer.

Prithviraj Bose, MD, MD Anderson Cancer Center

Latest:

Well-Differentiated Systemic Mastocytosis vs Chronic Mast Cell Leukemia

The panel of experts discuss the clinical differences between well-differentiated systemic mastocytosis and chronic mast cell leukemia.

Amy Valley, PharmD

Latest:

Community-Based Oncology Practices Adapt to Uncertainty of Pandemic

The impact of COVID-19 has been felt deeply by community-based oncologists.

Tilak Sundaresan, MD

Latest:

Dr Sundaresan on Reasons Why Patients With Pancreatic Cancer May Decline Treatment

Tilak Sundaresan, MD, on results of a retrospective study of reasons why patients with pancreatic cancer decline treatment.

Christian S. Hinrichs, MD

Latest:

Dr. Hinrichs on Unmet Needs with Cellular Therapy in Metastatic Epithelial Cancer

Christian S. Hinrichs, MD, discusses unmet needs with cellular therapies in metastatic epithelial cancer.

Charles Schiffer, MD

Latest:

Dr. Schiffer on Factors to Consider for TKI Discontinuation in CML

Charles Schiffer, MD, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia.

Yongfeng He, PhD

Latest:

Dr. He Discusses Discovery of Cancer-Inducing Mutation in Thymic Epithelial Cells

Yongfeng He, PhD, discusses the identification of the GTF2I L424H mutation in mouse models of thymic cancer.

Jeanny B. Aragon-Ching, MD, FACP

Latest:

Considerations When Treating Patients With Metastatic Renal Cell Carcinoma

Similar to first-line therapy choices, particular treatment factors, including type and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.

Rachna Shroff, MD, University of Arizona

Latest:

Dr. Shroff on Unmet Needs in Advanced Biliary Tract Cancer

Rachna T. Shroff, MD, MS, discusses unmet needs in advanced biliary tract cancer.

O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham

Latest:

Bredel Findings Address Understanding of Diffuse Gliomas

A groundbreaking discovery by Markus Bredel, MD, PhD, and colleagues not only marks a significant milestone in our understanding of diffuse gliomas but also paves the way for improved predictions of disease outcomes and the development of targeted treatment approaches.

Claire Roddie, MD, PhD

Latest:

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Claire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.

Karen S. Anderson, MD, PhD

Latest:

Dr Anderson on Novel and Emerging Therapeutics in HR+ Breast Cancer

Karen S. Anderson, MD, PhD, discusses novel and emerging therapies, as well as potential future targets, for the treatment of patients with hormone receptor–positive breast cancer.

Associate Editor,

Latest:

Real-World Analysis Shows Superior Efficacy With Cilta-Cel vs Ide-Cel in R/R Multiple Myeloma

Pooja Phull, MD, discusses real-world responses and survival outcomes with cilta-cel vs ide-cel in patients with relapsed/refractory multiple myeloma.